Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

FDA Calls Glaxo Ad For Prostate Drug ‘Misleading’

By Pharmaceutical Processing | March 2, 2009

By MATTHEW PERRONE AP Business Writer WASHINGTON (AP) — A marketing campaign for a GlaxoSmithKline prostate drug has drawn complaints from federal regulators, who said the space-themed advertisement is misleading. The British drugmaker’s Avodart capsules treat symptoms of enlarged prostate, including frequent urination. In the company’s advertisement, a man working on a model of the solar system is forced to stop painting to make frequent trips to the bathroom. A colleague then recommends he take Avodart, adding that “other medicines, they don’t treat the cause, because they don’t shrink the prostate.” But FDA regulators say that claim is false. In a letter to the company’s U.S. management, the FDA said Merck & Co. Inc.’s Proscar also reduces the size of the prostate, and has a similar indication. “Nothing in the labeling for Avodart suggests any specific advantage,” states the FDA letter, which was posted online Friday. Regulators also take issue with the visuals used to promote the drug. At one point the ad shows a man holding a model of a planet which is quickly replaced with a much smaller planet, to demonstrate Avodart’s prostate-shrinking power. The FDA says the visual exaggerates the drug’s effect, which has been shown to reduce the prostates size about 25 percent after two years. “The planet shrinking in size represents a reduction in prostate volume that is much greater than the reduction actually achieved with Avodart,” states the agency. The FDA’s letter, dated last week, calls on the company to respond to the agency’s concerns by March 4. Company spokeswoman Sarah Alspach said in a statement Friday the ad has not aired since last fall, and that the company “is committed to responsible marketing.” The company’s U.S. operations are based in Research Triangle Park, N.C. The FDA regularly issues warning letters to companies that do not follow regulations for manufacturing and marketing. The letters are not legally binding, but the agency can take companies to court if they are ignored. Avodart won approval in the U.S. in 2001 has become a strong revenue driver for Glaxo, the world’s second-largest drugmaker. The company is also testing the drug as a preventive treatment against prostate cancer. Enlarged prostate affects half of men over 50 and 90 percent of men over 80.

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards